Tandem Diabetes Care, Inc. Completes $23 Million Underwritten Public Offering

Represented Tandem Diabetes Care, Inc. (NSDQ:TNDM) with its follow-on underwritten public offering of 18,500,000 shares of its common stock, including 500,000 shares sold pursuant to the partial exercise of the underwriters’ overallotment option, at a public offering price of $1.25 per share for gross proceeds of approximately $23.1 million.  The Sole Book-Running Manager was Piper Jaffray & Co. and the Co-Managers were Oppenheimer & Co. Inc. and Wedbush Securities Inc.

Tandem, based in San Diego, California, is a medical device company with an innovative, user-centric and integrated approach to the design, development and commercialization of products for people with diabetes who use insulin. Among other products, Tandem manufactures and sells the t:slim G4™ Insulin Pump, the first CGM-enabled pump with touch-screen simplicity.